Clinical trials: Refractory Overactive Bladder
Overactive Bladder, Urinary Incontinence
Add-on Mirabegron in Pediatric Patients With Refractory Overactive Bladder
The objective is to evaluate the efficacy and safety of adding mirabegron to an antimuscarinic to treat urinary incontinence in children with Overactive Bladder that are refractory to antimuscarinics.
- Trial name
- Add-on-Mira (NCT02476175)
- Testing
- Mirabegron
- Volunteers
- 35 people
- Sponsor
- CHU de Quebec-Universite Laval
Overactive Bladder
Comparative Efficacy and Safety if Intravesical Botulinum Toxin A Versus Platelet-Rich Plasma in the Management of Refractory Overactive Bladder : A 2 Year Study
The goal of this clinical trial is to compare the efficacy and safety of intravesical Botulinum Toxin A versus intravesical Platelet-Rich Plasma (PRP) in adults with refractory overactive bladder who have not responded adequately…
- Trial name
- NCT07693192
- Testing
- Intravesical Botulinum Toxin A (100U), Intravesical Platelet-Rich Plasma
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Mahmoud Mohamed Farag Ali
Overactive Bladder
The Use of cineMRI to Evaluate Botox in Patients With Medication Refractory Overactive Bladder
With the goal of providing improved treatment to patients with overactive bladder symptoms (OAB), the investigators seek to apply the new technology of time-resolved (cine) MRI combined with urodynamics (UDS) to understand the…
- Trial name
- NCT02315950
- Testing
- Botulinum toxin and cineMRI-UDS
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Cedars-Sinai Medical Center
Parkinson's Disease, Multiple System Atrophy
Botulinum A Toxin in Patients With Parkinson's Disease
The researchers investigated the effectiveness and safety of BoNT/A injected into the detrusor muscle in patients with PD and MSA all of whom had detrusor muscle overactivity unresponsive to conventional medical therapy.
- Conditions
- Parkinson's Disease, Multiple System Atrophy, Detrusor Overactivity
- Trial name
- Botox-PD (NCT00822913)
- Testing
- Intravesical injection of Botulinum A toxin
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University Of Perugia
Urinary Bladder, Overactive
The Efficacy of Intravaginal Electrical Stimulation in Women With Idiopathic Overactive Bladder
In this study, it was aimed to compare the effectiveness of intravaginal electrical stimulation (IVES) added to bladder training (BT) on quality of life (QoL) and clinical parameters related to overactive bladder (OAB) in…
- Trial name
- NCT05416450
- Testing
- intravaginal electrical stimulation added to bladder training
- Where
- Turkey (Türkiye)
- Volunteers
- 48 people
- Sponsor
- Pamukkale University
Overactive Bladder (OAB), Premature (Early) Ejaculation
Effect of Antimuscarinic Treatment on Premature Ejaculation Severity in Men With Overactive Bladder: a Prospective Comparison With Mirabegron
Overactive bladder (OAB) is a condition characterized by involuntary bladder contractions. Antimuscarinic drugs are commonly used to treat OAB by blocking muscarinic receptors (M2 and M3) in the bladder.
- Conditions
- Overactive Bladder (OAB), Premature (Early) Ejaculation, Ejaculation Abnormal
- Trial name
- NCT07736560
- Testing
- Tolterodine, Mirabegron (beta3-adrenoceptor agonist)
- Where
- Turkey (Türkiye)
- Volunteers
- 40 people
- Sponsor
- Başakşehir Çam & Sakura City Hospital
Overactive Bladder
This is a Prospective, Randomized, Double-Blind Study Comparing Intravesical Injection of Botox® to Placebo.
The current study will investigate the comparative efficacy, safety and patient satisfaction of intradetrusor injections BOTOX® injections (200U) versus placebo (saline) injections in the treatment of OAB secondary to benign…
- Trial name
- BTX0621 (NCT00479596)
- Testing
- Botox
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Urological Sciences Research Foundation
Overactive Bladder
An Implantable Microstimulator for the Chronic Treatment of Urinary Urgency-Frequency Syndrome
The goal of this study is to investigate the safety and effectiveness of a new implanted device designed to treat Urinary Urgency-Frequency Syndrome.
- Trial name
- NCT00131573
- Testing
- bion
- Where
- 11 sites in United States
- Volunteers
- 118 people
- Sponsor
- Boston Scientific Corporation
Overactive Bladder, Bladder, Overactive
Transvaginal Botulinum Toxin A Chemodenervation for Overactive Bladder
Overactive bladder (OAB) is a highly prevalent disease process that, when refractory to oral medication therapy, can be effectively managed with injection of botulinum toxin A (BTA) into the detrusor muscle of the bladder.
- Conditions
- Overactive Bladder, Bladder, Overactive, Urge Incontinence, Urgency Urinary
- Trial name
- FETOC (NCT05463822)
- Testing
- Transvaginal botulinum toxin A (BTA) injection
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Stanford University
Urinary Bladder, Overactive
Unilateral Versus Bilateral Neuromodulation Tests in the Treatment of Refractory Idiopathic Overactive Bladder
The primary objective of this study is to compare the efficacy of unilateral and bilateral neuromodulation tests at 1 month.
- Trial name
- HAVIR Bi (NCT01558856)
- Testing
- Unilateral electrode placement and testing, Bilateral electrode placement and testing
- Where
- 6 sites in France
- Volunteers
- 55 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Overactive Bladder
Efficacy and Safety of Botulinum Toxin A for the Treatment of Refractory Overactive Bladder.
Overactive bladder induce urgency, urge incontinence, nocturia and pollakiuria. This condition is often resistant to anticholinergic drugs used as a first line treatment for this purpose.
- Trial name
- NCT00231491
- Testing
- Botulinum Toxin A (Botox )
- Where
- France
- Volunteers
- 160 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris